Clinical Research Directory
Browse clinical research sites, groups, and studies.
sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.
Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Summary
* Preeclampsia (PE) affects \~5% of pregnancies. Although improved obstetrical care has significantly diminished associated maternal mortality, PE remains a leading cause of maternal morbidity and mortality in the world. * Term PE accounts for 70% of all PE and a large proportion of maternal-fetal morbidity related with this condition. Prediction and prevention of term PE remains unsolved. * Previously proposed approaches are based on combined screening and/or prophylactic drugs, but these policies are unlikely to be implementable in many world settings. * Recent evidence shows that sFlt1-PlGF ratio at 35-37w predicts term PE with 80% detection rate. * Likewise, recent studies demonstrate that induction of labor (IOL) from 37w is safe. * The investigators hypothesize that a single-step universal screening for term PE based on sFlt1/PlGF ratio at 35-37w followed by IOL from 37w would reduce the prevalence of term PE without increasing cesarean section rates or adverse neonatal outcomes. * The investigators propose a randomized clinical trial to evaluate the impact of a screening of term PE with sFlt-1/PlGF ratio in asymptomatic nulliparous women at 35-37w. Women will be assigned to revealed (sFlt-1/PlGF known to clinicians) versus concealed (unknown) arms. A cutoff of \>90th centile will be used to define high risk of PE and offer IOL from 37w. * If successful, the results of this trial will provide evidence to support a simple universal screening strategy reducing the prevalence of term PE, which could be applicable in most healthcare settings and have enormous implications on perinatal outcomes and public health policies worldwide.
Official title: Protocol of the PE37 Study: A Multicenter Randomized Trial of Screening With sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
9132
Start Date
2021-03-02
Completion Date
2026-12-31
Last Updated
2025-02-19
Healthy Volunteers
Yes
Conditions
Interventions
sFlt1/PlGF screening in maternal blood at 35 to 36.6 weeks of gestation
A ratio cutoff of \>p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation
Locations (21)
CHU Liège
Liège, Belgium
Clinica del Prado SAS
Bogotá, Colombia
Institute for the Care of Mother and Child
Prague, Czechia
Medicina Fetal Quito
Quito, Ecuador
Maulana Azad Medical College (MAMC)
New Delhi, National Capital Territory of Delhi, India
All India Institute of Medical Sciences (AIIMS) Ansari Nagar
New Delhi, National Capital Territory of Delhi, India
Vardhman Mahavir Medical College (VMMC)
New Delhi, National Capital Territory of Delhi, India
Hospital Gineco-Obstetricia nº4
Mexico City, Mexico
Hospital Santo Tomas
Panama City, Panama
Centre of Postgraduate Medical Education, Obstetrics and Gynecology and Perinatal Medicine
Warsaw, Poland
Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain
Complejo Hospitalario Universitario Insular Materno Infantil
Las Palmas de Gran Canaria, Canary Islands, Spain
Virgen de la Arrixaca
El Palmar, Murcia, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital del Mar
Barcelona, Spain
Hospital Maternitat del Clínic
Barcelona, Spain
Hospital Sant Joan de Déu
Barcelona, Spain
Hospital La Paz
Madrid, Spain
Hospital Son Llatzer
Palma de Mallorca, Spain
Hospital la Fe
Valencia, Spain
Hospital Lozano Blesa
Zaragoza, Spain